TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend” or “the Company”) today announced that it anticipates 2019 full year revenue exceeding CAD$135 million.¹

Key drivers of 2019 revenue include:

• Anticipated revenue attributable to the acquisition of The Apothecarium (anticipated closing in Q2 2019);
• Continued growth in Canada in both the medical and adult-use markets, fueled by the ongoing expansion of the Company’s Mississauga facility (to be completed in Q2 2019) and commencement of pharmaceutical and nutraceutical compounding activities at the Drug Preparation Premises (DPP);
• Worldwide sales growth of hemp-derived products developed, manufactured, and distributed by Arise Bioscience; and
• Export of THC and hemp-based CBD products to Germany and other international markets once GMP certification is obtained (expected in the coming weeks).

The Company expects to open new Apothecarium locations in Berkeley, California and Philipsburg, New Jersey as well as a fully vertically integrated cultivation, extraction and processing facility in Boonton, New Jersey in Q4 2019.  The Company has not included revenue from these operations in 2019 guidance.

“We are seeing the results of the foundation we laid in 2018.  Our team is focused on operational excellence in our facilities across North America, continuing to procure new licenses across the US through greenfield license applications and strategic acquisitions of existing operations.  On behalf of all of the employees of TerrAscend, we pledge to continue our hard work and efforts in our goal of exceeding patient, customer and stakeholder expectations.” said Matthew Johnson, President of TerrAscend Corp., and TerrAscend USA, Inc.

On April 24, the Company will release its 2018 annual audited financial statements and will host an Investor Day on April 25.

SOURCE